SV

Street Verdict

Analyst Scorecard

FORTIS · NSE

Fortis Healthcare Limited

₹825

+1.87% (+₹15.15)

Prev. close

₹809.85

Volume

22,88,213

Delivery %

35.3%

As of

20 Nov 2026

Price history

₹825-₹91.7 (-10.00%) · 3M
18 Aug 2026 → 20 Nov 2026
75080085090018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Long-Horizon calls · 1yr+ horizon · verdict pending

CallAnalystInstrumentVerdictActions
Market commentary · 8 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Fortis Healthcare Limited

Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.

Details

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Dr. Ashutosh Raghuvanshi

Headquarters

Gurugram

Employees

14,649

Key stats

Market cap

₹59,445.41 Cr

P/E ratio (TTM)

56.7

Dividend yield

0.13%

EPS (TTM)

₹13.88

Beta (1Y · daily vs NIFTY 50)

0.74

Beta (5Y · monthly vs NIFTY 50)

1.41

Shares float

48.93 Cr

EPS · quarter ended Jun 2026

₹3.53

Financial Performance

01 · Financials

-5000 Cr0 Cr5000 Cr10000 Cr₹-10%0%10%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-1001020₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

00111₹0%0.1%0.2%0.3%20 Jul 2324 Jul 2425 Jul 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹4,030.12 Cr₹5,717.61 Cr₹6,297.63 Cr₹6,892.92 Cr₹7,782.75 Cr₹9,127.84 Cr
EBITDA
₹452.21 Cr₹1,411.33 Cr₹1,237.80 Cr₹1,308.51 Cr₹1,547.49 Cr₹2,097.86 Cr
₹-109.76 Cr₹555.12 Cr₹588.73 Cr₹598.88 Cr₹774.21 Cr₹1,041.78 Cr
Diluted EPS
₹-1.45₹7.35₹7.8₹7.93₹10.26₹13.8

Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹-109.76 Cr while the annual report gives ₹-56.17 Cr (48.8% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹91.49 Cr) is left blank here too, rather than shown from only one of the two sources.

EBITDA for Mar 2022 could not be checked against the company's own annual report: this page shows ₹1,411.33 Cr while the annual report gives ₹1,096.30 Cr (22.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹662.16 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹10,866.00 Cr₹11,516.00 Cr₹12,089.00 Cr₹12,971.00 Cr₹13,377.00 Cr₹15,833.00 Cr
₹1,530.55 Cr₹1,254.93 Cr₹925.72 Cr₹1,155.02 Cr₹2,475.11 Cr₹3,472.58 Cr
Stockholders' equity
₹6,120.00 Cr₹6,178.00 Cr₹7,242.00 Cr₹7,663.00 Cr₹8,917.00 Cr₹9,896.00 Cr

Trade receivables, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹485.00 Cr₹865.00 Cr₹822.00 Cr₹1,100.00 Cr₹1,424.00 Cr₹1,601.00 Cr
Investing cash flow
₹-135.11 Cr₹-514.38 Cr₹-373.70 Cr₹-886.35 Cr₹-779.38 Cr₹-1,538.41 Cr
₹-143.00 Cr₹-517.00 Cr₹-471.00 Cr₹-86.00 Cr₹-714.00 Cr₹164.00 Cr
Capital expenditure
₹-218.51 Cr₹-215.49 Cr₹-447.24 Cr₹-942.47 Cr₹-846.94 Cr₹-945.53 Cr
End cash position
—₹66.60 Cr₹45.14 Cr₹169.66 Cr₹99.91 Cr₹328.32 Cr

End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Jun 26(20Q)
Promoter31.17%
Public68.83%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Fortis Healthcare Limited₹59,445.41 Cr₹790.6556.76.0110.5%0.35+17.1%-22.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

FORTIS

Max Healthcare, Apollo Hospitals, other healthcare stocks surge over 5% despite volatile market; what’s behind the surge?

Upstox · 3 days ago

FORTIS

Max Healthcare stock highlights H1 growth and bed expansion

ad-hoc-news.de · 3 days ago